FANGZHOU JIANKE (06086) has announced its financial results for 2025, revealing a significant 30.2% year-on-year increase in revenue to RMB 3.53 billion. The company achieved a net profit of RMB 11.832 million, marking a turnaround from a loss in the previous year.

Key platform metrics demonstrated continued growth. The average monthly active users over the twelve months ended December 31, 2025, rose by 35% to 13.7 million. Furthermore, the total number of registered doctors exceeded 251,000 by the end of the reporting period.

The revenue growth was primarily driven by increases in online retail pharmacy services, wholesale operations, and comprehensive healthcare services. This was partially offset by a decrease in revenue from customized content and marketing solutions.

Revenue generated from online retail pharmacy services increased by 33.4% year-on-year to RMB 1.8734 billion. This growth stemmed from higher sales of pharmaceuticals and health products, benefiting from an expanding user base and increased platform engagement. Revenue from comprehensive healthcare services grew by 21.9% to RMB 788 million, while wholesale revenue saw a 41.6% increase to RMB 780 million.

During the reporting period, the policy and regulatory landscape continued to guide the long-term, rapid development of the healthcare industry. The company benefited from a favorable policy environment focused on the digital economy and the transition towards the "16th Five-Year Plan" period. National-level policies prioritizing "AI + healthcare" and the prevention and management of chronic diseases have accelerated the industry's shift towards a patient-centric model. This digital transformation has also enhanced the efficiency of healthcare resource allocation. As an early mover, the company has integrated these priorities into its strategic planning, focusing on ensuring sustainable growth that aligns with policy directions.